XmAb20717 in Advanced Biliary Tract Cancers
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Biliary Tract Cancer
DRUG: XmAb20717
Objective Response Rate (ORR), Proportion of participants with the best response being complete response (CR) or partial response (PR), From therapy initiation, assessed at each restaging scan, for up to 24 months
Progression-free survival, Time from study enrollment until disease progression or death with censoring for loss to follow up, From therapy initiation until progression or death, whichever comes first, for up to 60 months|Overall survival, Time from study enrollment until death, From therapy initiation until death, for up to 60 months|Objective Response Rate (ORR) in patients that received prior immunotherapy, Proportion of participants with the best response being complete response (CR) or partial who received prior immunotherapy., From therapy initiation, assessed at each restaging scan, for up to 24 months|Objective Response Rate (ORR) in patients who did not received prior immunotherapy, Proportion of participants with the best response being complete response (CR) or partial who did not receive prior immunotherapy., From therapy initiation, assessed at each restaging scan, for up to 24 months
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.